Oral Session 2-14A CAR T Therapy

[OS2-14A-1] Combined anti-mesothelin CART cells with oncolytic viruses for the treatment of pancreatic cancer

Keisuke Watanabe^1,2, Luo Yanping², Da Tong², Guedan Sonia^2,3, Ruella Marco^2,3, John Scholler², Keith Brian², Young Regina², Engels Boris⁴, Sorsa Suvi^5,6, Siurala Mikko^5,6, Tahtinen Siri^5,6, Hemminki Akseli^5,6,7, June Carl^2,3,8 (1.Department of Hematology, Nagoya University, Nagoya, Japan, 2.Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, 3.Parker Institute for Cancer Immunotherapy, University of Pennsylvania, 4.Dpt. Immuno-Oncology, Novartis Institutes for BioMedical Research, 5.Cancer Gene Therapy Group, University of Helsinki, 6.TILT Biotherapeutics Ltd, 7.Helsinki University Comprehensive Cancer Center, 8.Dpt. Pathology and Laboratory Medicine, University of Pennsylvania)